These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27641475)

  • 1. Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.
    Perosky JE; Khoury BM; Jenks TN; Ward FS; Cortright K; Meyer B; Barton DK; Sinder BP; Marini JC; Caird MS; Kozloff KM
    Bone; 2016 Dec; 93():79-85. PubMed ID: 27641475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.
    Olvera D; Stolzenfeld R; Marini JC; Caird MS; Kozloff KM
    J Bone Miner Res; 2018 Jul; 33(7):1272-1282. PubMed ID: 29544018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.
    Sinder BP; Eddy MM; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    J Bone Miner Res; 2013 Jan; 28(1):73-80. PubMed ID: 22836659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.
    Sinder BP; Lloyd WR; Salemi JD; Marini JC; Caird MS; Morris MD; Kozloff KM
    Bone; 2016 Mar; 84():222-229. PubMed ID: 26769006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
    Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
    Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients.
    Surowiec RK; Battle LF; Ward FS; Schlecht SH; Khoury BM; Robbins C; Wojtys EM; Caird MS; Kozloff KM
    Bone; 2020 Jan; 130():115118. PubMed ID: 31678490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.
    Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B
    J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
    Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
    Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
    Sun W; Shi Y; Lee WC; Lee SY; Long F
    Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone matrix properties in adults with osteogenesis imperfecta are not adversely affected by setrusumab-a sclerostin neutralizing antibody.
    Rummler M; Schemenz V; McCluskey S; Davydok A; Rauch F; Glorieux FH; Harrington MJ; Wagermaier W; Willie BM; Zimmermann EA
    J Bone Miner Res; 2024 Sep; 39(9):1229-1239. PubMed ID: 38982734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin antibody enhances implant osseointegration in bone with Col1a1 mutation.
    Sung HH; Kwon HH; Stephan C; Reynolds SM; Dai Z; Van der Kraan PM; Caird MS; Blaney Davidson EN; Kozloff KM
    Bone; 2024 Sep; 186():117167. PubMed ID: 38876270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
    Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
    Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
    Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cortical bone properties in the Brtl/+ mouse model of Osteogenesis imperfecta as evidenced by acoustic transmission microscopy.
    Blouin S; Fratzl-Zelman N; Roschger A; Cabral WA; Klaushofer K; Marini JC; Fratzl P; Roschger P
    J Mech Behav Biomed Mater; 2019 Feb; 90():125-132. PubMed ID: 30366302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.
    Uveges TE; Kozloff KM; Ty JM; Ledgard F; Raggio CL; Gronowicz G; Goldstein SA; Marini JC
    J Bone Miner Res; 2009 May; 24(5):849-59. PubMed ID: 19113917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
    Cardinal M; Tys J; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Bone; 2019 Jul; 124():137-147. PubMed ID: 31051315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading.
    Spatz JM; Ellman R; Cloutier AM; Louis L; van Vliet M; Suva LJ; Dwyer D; Stolina M; Ke HZ; Bouxsein ML
    J Bone Miner Res; 2013 Apr; 28(4):865-74. PubMed ID: 23109229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.
    Masci M; Wang M; Imbert L; Barnes AM; Spevak L; Lukashova L; Huang Y; Ma Y; Marini JC; Jacobsen CM; Warman ML; Boskey AL
    Bone; 2016 Jun; 87():120-9. PubMed ID: 27083399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.